Quantoom, Memorial Sloan Kettering Partner to Develop Personalized Cancer Therapies

Quantoom Biosciences (Quantoom) and Memorial Sloan Kettering Cancer Center (MSK) have entered into a non-exclusive research license and supply agreement intended to support development of personalized cancer therapies with Quantoom’s Ncapsulate QCX-002, the company’s proprietary lipid nanoparticle (LNP) formulation technology (1). In the initial development phase, MSK will target deploying QCX-002 in at least one RNA-based medicine that is anticipated to enter the Phase I clinical trial stage.

“This agreement with MSK marks a major milestone for Quantoom and validates the potential of our QCX formulation chemistries in human therapeutic applications,” said José Castillo, CEO of Quantoom Biosciences, in a company press release (1). “It is an honor to collaborate with one of the most prestigious cancer research institutions in the world to help advance personalized RNA-based medicines.”

How will this partnership work?

In the press release, Quantoom said it will supply QCX-002 directly to MSK to enable the cancer center’s R&D efforts for personalized therapeutic products that target human cancers (1). The agreement has an option to expand the license for future potential developments in Quantoom’s proprietary library, and MSK will monitor any further RNA manufacturing technologies that Quantoom may develop.

“We are thrilled to partner with Quantoom to advance personalized therapeutics for patients battling deadly cancers,” said Vinod Balachandran, MD, director of the Olayan Center for Cancer Vaccines (OCCV) at MSK (1). “The powerful union of cutting-edge innovation and deep expertise, such as this, is precisely what’s needed to accelerate the development of breakthrough cancer medicines.”

What other partnerships has Quantoom launched in 2025?

Quantoom announced on March 5, 2025 that it would be collaborating with TechInvention Lifecare Pvt. Ltd. for the accessibility, scalability, and affordability of RNA-based vaccines, signing a memorandum of understanding during the Belgian Economic Mission to India that month (2). TechInvention said it would use Quantoom’s RNA N-Force toolbox to de-risk and accelerate the development of RNA-based vaccines from sequence design with Quantoom’s Ncode, RNA production with its Ntensify product, and encapsulation with the lipid-like delivery chemistry in bulk with Ncapsulate.

In June 2025, Quantoom signed a non-exclusive license and supply agreement with TriLink Biotechnologies, under the terms of which Quantoom will gain access to TriLink’s messenger RNA (mRNA) capping technology, known as CleanCap (3). The agreement called for CleanCap to be integrated into Quantoom’s Ntensify self-amplifying mRNA production platform, which the two companies said will help to accelerate the RNA production process.

Are there other links between LNP innovation and cancer treatment?

In July 2025, NanoCell Therapeutics spotlighted data published in the Journal for ImmunoTherapy of Cancer regarding the company’s novel targeted LNP delivery system, NCtx, which enables direct in-vivo generation of chimeric antigen receptor T-cells (CAR-T)—a process that NanoCell believes can transform the scalability and accessibility of CAR-T therapies for cancer patients (4).

Shada Warreth, Global Partnerships Implementation senior manager at NIBRT and PhD Candidate at TU Dublin, Ireland, examined the manufacturing journey for CAR-T cellular therapy and how it relates to RNA’s relevance in cancer treatments in a Sept. 8, 2025 piece for BioPharm International®.

“The introduction of CARs into the T cells is usually achieved using viral vectors, such as lentiviral or gamma retroviral vectors (the main two classes of retroviral vectors that are derived from enveloped RNA viruses of the retroviridae family), adenoviruses, and adeno-associated viruses,” Warreth wrote (5). “These vectors deliver the genetic load into the T cells, leading to the expression of CARs on the cell surface. This genetic modification provides the T cells with the ability to identify and destroy cancer cells, effectively turning them into CAR-T cells.”

MSK plans to house its collaborative efforts with Quantoom at OCCV, which MSK describes as an “academic biohub for personalized cancer immunotherapies” (1).

References

1. Quantoom Biosciences. Quantoom Biosciences Signs Research License and Supply Agreement with Leading Global Cancer Center for mRNA Formulation Technology in Personalized Cancer Therapeutics. Press Release. Sept. 25, 2025.
2. Haigney, S. TechInvention and Quantoom Biosciences Collaborate on RNA-Based Vaccines. BioPharmInternational.com, March 5, 2025.
3. Lavery, P. TriLink and Quantoom Ink License and Supply Agreement for mRNA Capping Technology. BioPharmInternational.com, June 4, 2025.
4. Lavery, P. NanoCell’s LNP Platform Shows Promise for In-Vivo CAR-T Development. BioPharmInternational.com, Aug. 6, 2025.
5. Warreth, S. The Manufacturing Journey of CAR-T Cellular Therapy—An Overview. BioPharmInternational.com, Sept. 8, 2025.